Powder: -20°C for 3 years
In solvent: -80°C for 6 months
SDMA is the most potent endogenous inhibitor of nitric oxide synthase (NOS), with higher levels in patients with end-stage renal disease (ESRD).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | 47.00 | |
10 mg | In stock | 51.00 | |
25 mg | In stock | 101.00 | |
50 mg | In stock | 174.00 | |
100 mg | In stock | 304.00 | |
1 mL * 10 mM (in DMSO) | In stock | 50.00 |
Description | SDMA is the most potent endogenous inhibitor of nitric oxide synthase (NOS), with higher levels in patients with end-stage renal disease (ESRD). |
Targets&IC50 | Human Endogenous Metabolite |
In vitro | SDMA inhibited dose dependently the NO synthesis in intact endothelial cells, whereas it had no effect on protein expression of NOS. This effect was associated with an increase in reactive oxygen species. Co-incubation with L-arginine but not D-arginine reversed the effect of SDMA on NOS pathway. Suggest that SDMA reduced the endothelial NO synthesis, probably by limiting L-arginine supply to NOS. It is concluded that SDMA might be a useful parameter for detecting patients in very early stages of chronic kidney disease and for determining their risk for developing cardiovascular disease[1]. |
Synonyms | Symmetric dimethylarginine , NG,NG'-Dimethyl-L-arginine |
Purity | 98.00% |
Molecular Weight | 202.25 |
Formula | C8H18N4O2 |
CAS No. | 30344-00-4 |
Powder: -20°C for 3 years
In solvent: -80°C for 6 months
DMSO: 50 mg/mL (247.22 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.